SK Plasma announced its largest technology export deal to date, securing a 65 million euro ($75 million) technology transfer and licensing agreement with Proturk, a joint venture supported by the Turkish Red Crescent. This partnership aims to establish domestic plasma fractionation capabilities in Turkey.
The agreement represents the most significant single contract for SK Plasma since its founding in 2015, solidifying its position in the biopharmaceutical industry.
The agreement allows Proturk to manufacture plasma-derived pharmaceuticals at a future production site in Turkey, with SK Plasma providing the necessary research, development, and production technologies.
SK Plasma is also investing 150,000 euros for a 15 percent stake in Proturk, entitling the company to dividends based on the joint venture’s financial performance.
Leveraging the operational expertise from its plasma fractionation plant located in Andong, North Gyeongsang Province, the South Korean biopharmaceutical firm plans to commence technology transfer operations with its Turkish counterparts.
SK Plasma intends to develop standardized technology transfer manuals to mitigate potential risks that may occur during the implementation process.
Upon completion of the production facility in Cubuk, Ankara, Turkey will be capable of producing vital plasma-derived medicines, including albumin and immune globulin, thereby eliminating reliance on imports.
“We plan to enhance our collaboration with the Turkish government to improve access to essential medicines and contribute to building robust healthcare safety nets,” said Kim Seung-joo, CEO of SK Plasma.
“This initiative goes beyond a simple technology export, demonstrating the transfer of SK Plasma’s full operational framework to domestic facilities.”
stlee0329
